$RSLS
ReShape Lifesciences Inc. Stock $rsls

$rsls Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000142757020000047 Filed on July 30, 2020

Income Statement

Concept	2020 Q2	2019 Q2
Revenue	$1.702M	$386.0K
YoY Change	340.93%	-85.87%
Cost Of Revenue	$865.0K	$679.0K
YoY Change	27.39%	-60.8%
Gross Profit	$837.0K	-$293.0K
YoY Change	-385.67%	-129.3%
Gross Profit Margin	49.18%	-75.91%
Selling, General & Admin	$831.0K	$4.332M
YoY Change	-80.82%	-40.25%
% of Gross Profit	99.28%
Research & Development	$465.0K	$1.788M
YoY Change	-73.99%	-46.66%
% of Gross Profit	55.56%
Depreciation & Amortization	$84.00K	$430.0K
YoY Change	-80.47%	-69.06%
% of Gross Profit	10.04%
Operating Expenses	$3.835M	$6.120M
YoY Change	-37.34%	-42.28%
Operating Profit	-$2.998M	-$6.413M
YoY Change	-53.25%	-33.21%
Interest Expense	-$789.0K	-$295.0K
YoY Change	167.46%	417.54%
% of Operating Profit
Other Income/Expense, Net	-$26.00K	-$59.00K
YoY Change	-55.93%	-37.23%
Pretax Income	-$3.654M	-$16.51M
YoY Change	-77.86%	-19.56%
Income Tax	-$50.00K	-$586.0K
% Of Pretax Income
Net Earnings	-$3.604M	-$6.767M
YoY Change	-46.74%	-30.62%
Net Earnings / Revenue	-211.75%	-1753.11%
Basic Earnings Per Share	-$0.93
Diluted Earnings Per Share	-$0.93	-$150.2M
COMMON SHARES
Basic Shares Outstanding	3.896M	24.00M shares
Diluted Shares Outstanding	3.896M

Balance Sheet

Concept	2020 Q2	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.804M	$4.355M
YoY Change	56.23%	134.14%
Cash & Equivalents	$6.804M	$13.51M
Short-Term Investments		$0.00
Other Short-Term Assets	$3.971M	$954.0K
YoY Change	316.25%	11.32%
Inventory	$0.00	$2.107M
Prepaid Expenses	$640.0K	$954.0K
Receivables	$0.00	$447.0K
Other Receivables	$3.150M	$0.00
Total Short-Term Assets	$10.78M	$17.02M
YoY Change	-36.7%	-45.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.055M	$1.038M
YoY Change	1.64%	-31.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.295M	$563.0K
YoY Change	130.02%	603.75%
Total Long-Term Assets	$3.098M	$2.178M
YoY Change	42.24%	43.86%
TOTAL ASSETS
Total Short-Term Assets	$10.78M	$17.02M
Total Long-Term Assets	$3.098M	$2.178M
Total Assets	$13.87M	$19.20M
YoY Change	-27.74%	-40.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.054M	$1.082M
YoY Change	-2.59%	-25.12%
Accrued Expenses	$4.422M	$343.0K
YoY Change	1189.21%	-92.38%
Deferred Revenue	$123.0K	$320.0K
YoY Change	-61.56%	5.96%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$5.000M
YoY Change		26.1%
Total Short-Term Liabilities	$5.599M	$10.09M
YoY Change	-44.51%	-2.94%
LONG-TERM LIABILITIES
Long-Term Debt	$430.0K	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$666.0K	$0.00
YoY Change
Total Long-Term Liabilities	$1.096M	$722.0K
YoY Change	51.8%	-88.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.599M	$10.09M
Total Long-Term Liabilities	$1.096M	$722.0K
Total Liabilities	$6.695M	$10.81M
YoY Change	-38.08%	-34.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$181.9M	-$163.8M
YoY Change	11.05%	22.88%
Common Stock	$189.1M	$172.2M
YoY Change	9.79%	15.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.15M	$8.376M
YoY Change
Total Liabilities & Shareholders Equity	$13.87M	$19.20M
YoY Change	-27.74%	-40.87%

Cashflow Statement

Concept	2020 Q2	2019 Q2
OPERATING ACTIVITIES
Net Income	-$3.604M	-$6.767M
YoY Change	-46.74%	-30.62%
Depreciation, Depletion And Amortization	$84.00K	$430.0K
YoY Change	-80.47%	-69.06%
Cash From Operating Activities	-$2.750M	-$2.900M
YoY Change	-5.17%	-55.38%
INVESTING ACTIVITIES
Capital Expenditures	$209.0K	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	$209.0K	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	430.0K	5.427M
YoY Change	-92.08%	-27.93%
NET CHANGE
Cash From Operating Activities	-2.750M	-2.900M
Cash From Investing Activities	209.0K	0.000
Cash From Financing Activities	430.0K	5.427M
Net Change In Cash	-2.111M	2.527M
YoY Change	-183.54%	147.75%
FREE CASH FLOW
Cash From Operating Activities	-$2.750M	-$2.900M
Capital Expenditures	$209.0K	$0.00
Free Cash Flow	-$2.959M	-$2.900M
YoY Change	2.03%	-55.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001427570
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7731633	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Registrant Name EntityRegistrantName	OBALON THERAPEUTICS INC
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q4	obln	Accrued Customer Incentives Current AccruedCustomerIncentivesCurrent	198000	USD
CY2020Q2	obln	Accrued Customer Incentives Current AccruedCustomerIncentivesCurrent	0	USD
CY2019Q4	obln	Accrued Legal And Professional Fees Current AccruedLegalAndProfessionalFeesCurrent	412000	USD
CY2020Q2	obln	Accrued Legal And Professional Fees Current AccruedLegalAndProfessionalFeesCurrent	93000	USD
CY2019Q4	obln	Accrued Settlement Liability Current AccruedSettlementLiabilityCurrent	0	USD
CY2020Q2	obln	Accrued Settlement Liability Current AccruedSettlementLiabilityCurrent	3150000	USD
CY2020Q2	obln	Accrued Settlement Liability Current AccruedSettlementLiabilityCurrent	3150000	USD
	obln	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-136000	USD
	obln	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-147000	USD
CY2020Q2	obln	Lease Liability LeaseLiability	1245000	USD
CY2019Q4	obln	Lease Liability Current LeaseLiabilityCurrent	561000	USD
CY2020Q2	obln	Lease Liability Current LeaseLiabilityCurrent	579000	USD
CY2019Q4	obln	Lease Liability Noncurrent LeaseLiabilityNoncurrent	567000	USD
CY2020Q2	obln	Lease Liability Noncurrent LeaseLiabilityNoncurrent	666000	USD
CY2020Q2	obln	Lessee Liability Payments Due LesseeLiabilityPaymentsDue	1338000	USD
CY2020Q2	obln	Lessee Liability Undiscounted Excess Amount LesseeLiabilityUndiscountedExcessAmount	93000	USD
CY2019Q4	obln	Manufacturing Use Assets Current ManufacturingUseAssetsCurrent	0	USD
CY2020Q2	obln	Manufacturing Use Assets Current ManufacturingUseAssetsCurrent	166000	USD
	obln	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	186000	USD
	obln	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	239000	USD
CY2020Q2	obln	Sharebased Compensation Arrangementby Sharebased Payment Award Non Option Equity Instruments Vestedand Expectedto Vest Outstanding Aggregate Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsVestedandExpectedtoVestOutstandingAggregateIntrinsicValue	33000	USD
CY2020Q2	obln	Sharebased Compensation Arrangementby Sharebased Payment Award Non Option Equity Instruments Vestedand Expectedto Vest Outstanding Number SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsVestedandExpectedtoVestOutstandingNumber	46470	shares
CY2020Q2	obln	Sharebased Compensation Arrangementby Sharebased Payment Award Non Option Equity Instruments Vestedand Expectedto Vest Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsVestedandExpectedtoVestOutstandingWeightedAverageExercisePrice	9.60
	obln	Unpaid Stock Issuance Costs UnpaidStockIssuanceCosts	377000	USD
	obln	Unpaid Stock Issuance Costs UnpaidStockIssuanceCosts	0	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	648000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1054000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	285000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2326000	USD
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2458000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	188271000	USD
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	189049000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	15000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1105000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	536000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	470000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	292000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	70000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2019Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	112892	shares
CY2020Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2019Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1300000	USD
CY2020Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1310000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1310000	USD
CY2019Q4	us-gaap	Assets Assets	20393000	USD
CY2020Q2	us-gaap	Assets Assets	13873000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	18235000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	10775000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	14055000	USD
CY2020Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	6804000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14055000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6804000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21187000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13513000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14055000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6804000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7674000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7251000	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5311662	shares
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7724100	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7731633	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7724100	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7731633	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6767000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15057000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4188000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9449000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	424000	USD
CY2020Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	123000	USD
CY2019Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	315000	USD
CY2020Q2	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	0	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	679000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1911000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	423000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	964000	USD
CY2019Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	256000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300000	USD
CY2020Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	187000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000	USD
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.52
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.02
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.22
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	820000	USD
CY2020Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	240000	USD
CY2020Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	600000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2020Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	36000	USD
CY2020Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	24000	USD
CY2020Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	12000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-95000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	-293000	USD
	us-gaap	Gross Profit GrossProfit	250000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	280000	USD
	us-gaap	Gross Profit GrossProfit	519000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1200000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1257000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-191000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	405000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-423000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-285000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-32000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-302000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2712000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-564000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	157000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	524000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1760000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1845000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-142000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	2079000	USD
CY2019Q4	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	0	USD
CY2020Q2	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	3150000	USD
CY2020Q2	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	3150000	USD
CY2019Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-295000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-485000	USD
CY2020Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-5000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	30000	USD
	us-gaap	Interest Paid Net InterestPaidNet	563000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	89000	USD
CY2020Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	1936000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	0	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1835000	USD
CY2020Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	12000	USD
CY2020Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2020Q2	us-gaap	Inventory Write Down InventoryWriteDown	100000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	53000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1302000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	564000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	37000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	108000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	105000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	219000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	269000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	4544000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	6695000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20393000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13873000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3977000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5599000	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	567000	USD
CY2020Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1096000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2020Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	430000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3794000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	430000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2530000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-117000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13998000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7564000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-8290000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-6767000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15057000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-5261000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-4188000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9449000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	6120000	USD
	us-gaap	Operating Expenses OperatingExpenses	14763000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	4437000	USD
	us-gaap	Operating Expenses OperatingExpenses	9587000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6413000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14513000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4157000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9068000	USD
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	100000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	200000	USD
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	100000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	300000	USD
CY2020Q2	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	400000	USD
CY2020Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	100000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	200000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1077000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	748000	USD
CY2020Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	492000	USD
CY2020Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	277000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1959000	USD
CY2020Q2	us-gaap	Other Assets Current OtherAssetsCurrent	3971000	USD
CY2019Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	69000	USD
CY2020Q2	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	15000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1295000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1524000	USD
CY2020Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3603000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-59000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-59000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-411000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	117000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1890000	USD
CY2020Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	640000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8793000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	10000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	430000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	2550000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3407000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3513000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1081000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1055000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	15000000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1788000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4227000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	765000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2022000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-172430000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-181879000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-181900000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	400000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	386000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2161000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2200000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	703000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	700000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1500000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1483000	USD
CY2019Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	107000	USD
CY2020Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	83000	USD
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4332000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10536000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2362000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6255000	USD
CY2019Q2	us-gaap	Share Based Compensation ShareBasedCompensation	536000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1641000	USD
CY2020Q2	us-gaap	Share Based Compensation ShareBasedCompensation	292000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	762000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	191450	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	463000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.12
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	518468	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	790018	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.64
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.55
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	284649	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	46.65
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	693494	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	20.89
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	30.03
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.80
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M10D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y9M4D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y1M24D
CY2019Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	24859	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	581000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8074000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	15849000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	7178000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13107000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6518000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8376000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15849000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11072000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7178000	USD
CY2019Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.10
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2687829	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2500619	shares
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7728624	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7726915	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and trade accounts receivable, which are generally not collateralized. The Company limits its exposure to credit loss by placing its cash equivalents with high credit quality financial institutions and investing in high quality short-term debt instruments. The Company’s customers consisted of physicians and institutions in the United States and one international distributor. The Company establishes customer credit policies related to its accounts receivable based on historical collection experiences within the various markets in which the Company operates, historical past-due amounts, and any specific information that the Company becomes aware of such as bankruptcy or liquidity issues of customers. </font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</font></div></div>

Files In Submission

Name	View Source	Status
0001427570-20-000047-index-headers.html	Edgar Link	pending
0001427570-20-000047-index.html	Edgar Link	pending
0001427570-20-000047.txt	Edgar Link	pending
0001427570-20-000047-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
obln-20200630.xml	Edgar Link	completed
obln-20200630.xsd	Edgar Link	pending
obln-20200630_cal.xml	Edgar Link	unprocessable
obln-20200630_def.xml	Edgar Link	unprocessable
obln-20200630_lab.xml	Edgar Link	unprocessable
obln-20200630_pre.xml	Edgar Link	unprocessable
obln-63020x10q.htm	Edgar Link	pending
oblnex102.htm	Edgar Link	pending
oblnex311.htm	Edgar Link	pending
oblnex312.htm	Edgar Link	pending
oblnex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RSLS
ReShape Lifesciences Inc. Stock $rsls

2020 Q2 Form 10-Q Financial Statement

#000142757020000047 Filed on July 30, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSLS ReShape Lifesciences Inc. Stock $rsls

2020 Q2 Form 10-Q Financial Statement

#000142757020000047 Filed on July 30, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSLS
ReShape Lifesciences Inc. Stock $rsls